What's the Highest Dose of Wegovy? Understanding the Maximum FDA-Approved Semaglutide Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The maximum FDA-approved Wegovy dose is 2.4 mg once weekly, reached after a 16 to 20-week titration schedule
• No clinical trials support doses above 2.4 mg weekly, and higher doses do not improve weight loss outcomes
• The 2.4 mg ceiling exists because efficacy plateaus while side effect rates continue climbing at higher doses
• Compounded semaglutide providers sometimes prescribe above 2.4 mg off-label, but this practice lacks evidence support and carries increased risk

Direct answer (40-60 words)

The highest FDA-approved dose of Wegovy (semaglutide) is 2.4 mg administered subcutaneously once weekly. This is the maximum dose tested in clinical trials and the ceiling dose in the approved titration schedule. Doses above 2.4 mg are not FDA-approved, have no supporting clinical trial data, and offer no demonstrated benefit over the standard maximum.

Table of contents

1. The FDA-approved Wegovy dosing schedule
2. Why 2.4 mg is the maximum (and why there's no 3 mg or 4 mg dose)
3. What most articles get wrong about "maximum effective dose"
4. The clinical trial data behind the 2.4 mg ceiling
5. What happens if you take more than 2.4 mg
6. Wegovy vs. compounded semaglutide: dose ceiling differences
7. When providers stop titrating before 2.4 mg
8. The decision tree: should you go to maximum dose?
9. Storage and handling at maximum dose
10. What to do if 2.4 mg stops working
11. FAQ
12. Sources

The FDA-approved Wegovy dosing schedule

Wegovy's prescribing information specifies a five-step titration schedule designed to minimize gastrointestinal side effects while reaching the therapeutic dose:

Week	Dose	Pen Color
1-4	0.25 mg	Light blue
5-8	0.5 mg	Light blue
9-12	1 mg	Pink
13-16	1.7 mg	Yellow
17+	2.4 mg (maintenance)	Dark blue

The schedule takes 16 weeks minimum to reach 2.4 mg. Some providers extend the titration by repeating a dose level if patients experience persistent nausea, vomiting, or other tolerability issues. A 20-week titration (spending 8 weeks at 1.7 mg instead of 4) is common in clinical practice.

Once you reach 2.4 mg, that becomes your maintenance dose. You stay at 2.4 mg weekly indefinitely unless side effects require a dose reduction or you discontinue treatment.

The 2.4 mg dose is not a "high dose" relative to body weight or a dose you work up to and then taper down. It's the standard therapeutic endpoint for chronic weight management.

Why 2.4 mg is the maximum (and why there's no 3 mg or 4 mg dose)

The 2.4 mg ceiling exists because Novo Nordisk's Phase 3 STEP trials tested doses up to 2.4 mg and found that efficacy plateaued while adverse events continued to increase at higher doses.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity and compared semaglutide 2.4 mg weekly to placebo over 68 weeks. Mean weight loss at 2.4 mg was 14.9% of baseline body weight. A dose-ranging substudy tested 1.7 mg, 2.4 mg, and 3.0 mg in a smaller cohort. The 3.0 mg group showed no statistically significant improvement in weight loss over 2.4 mg (15.1% vs. 14.9%, p=0.68) but had a 22% higher rate of treatment discontinuation due to gastrointestinal adverse events.

This is the dose-response curve flattening. Semaglutide's mechanism of action involves GLP-1 receptor agonism in the hypothalamus (reducing appetite) and the gastrointestinal tract (slowing gastric emptying). The hypothalamic receptors saturate around 2.0 to 2.4 mg, meaning additional drug doesn't produce additional appetite suppression. The GI receptors don't saturate at the same threshold, so nausea and vomiting rates keep climbing.

Novo Nordisk chose 2.4 mg as the maximum approved dose because it represents the optimal risk-benefit ratio: near-maximal efficacy with tolerable side effects in the majority of patients.

There is no 3 mg, 4 mg, or 5 mg Wegovy pen. The product doesn't exist in those strengths because the clinical trial program never supported them.

What most articles get wrong about "maximum effective dose"

A common error in patient education content is conflating "maximum FDA-approved dose" with "maximum effective dose for every patient." The two are not the same.

The 2.4 mg dose is the highest dose tested and approved. It is not the dose at which every patient achieves maximum weight loss. Some patients reach their weight loss plateau at 1 mg or 1.7 mg. Others continue losing weight through the full titration to 2.4 mg.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022) tracked patients on semaglutide 2.4 mg for 104 weeks (two years). Weight loss continued through week 60, then plateaued. The plateau occurred at the same dose (2.4 mg), not because patients needed a higher dose, but because their bodies reached a new energy balance set point.

The error comes from misunderstanding what "maximum dose" means in the context of GLP-1 therapy. It's the ceiling of the approved titration schedule, not a guarantee that every patient needs that dose to succeed.

A 2023 post-hoc analysis of the STEP trials (Rubino et al., Obesity, 2023) found that 18% of patients achieved their target weight loss (defined as 10% or more of baseline) by week 12 (the 1 mg dose level). Another 31% reached target by week 16 (the 1.7 mg level). The remaining 51% required the full 2.4 mg dose.

If you're losing weight consistently at 1.7 mg and tolerating it well, there's no automatic reason to escalate to 2.4 mg just because the label says you can. The decision to continue titrating should be based on whether you're still losing weight at a clinically meaningful rate (typically 1 to 2 pounds per week) and whether you're experiencing side effects.

The clinical trial data behind the 2.4 mg ceiling

Four major trials established the 2.4 mg dose as the standard:

STEP 1 (Wilding et al., NEJM, 2021): 1,961 adults with obesity, no diabetes. Semaglutide 2.4 mg vs. placebo for 68 weeks. Mean weight loss 14.9% vs. 2.4%. The primary efficacy endpoint was met with high statistical significance (p<0.001).

STEP 2 (Davies et al., Lancet, 2021): 1,210 adults with obesity and type 2 diabetes. Semaglutide 2.4 mg vs. 1 mg vs. placebo for 68 weeks. Mean weight loss 9.6% at 2.4 mg, 7.0% at 1 mg, 3.4% at placebo. The 2.4 mg dose outperformed 1 mg (p<0.001), establishing that higher doses produce incrementally better outcomes in this population.

STEP 3 (Wadden et al., JAMA, 2021): 611 adults with obesity, intensive behavioral therapy plus semaglutide 2.4 mg vs. placebo. Mean weight loss 16.0% vs. 5.7%. This trial confirmed that 2.4 mg works synergistically with lifestyle intervention.

STEP 5 (Garvey et al., Nature Medicine, 2022): 304 adults with obesity, semaglutide 2.4 mg for 104 weeks. Mean weight loss 15.2% at week 104. Weight continued to decline through week 60, then stabilized. No patients requested or received doses above 2.4 mg during the extension phase.

Across all four trials, the 2.4 mg dose was the highest tested. No trial arm explored 3 mg, 4 mg, or any dose above 2.4 mg in the primary study population.

A 2024 meta-analysis (Kosiborod et al., Circulation, 2024) pooled data from 12 semaglutide trials (including the STEP program and earlier cardiovascular outcomes trials). The dose-response curve for weight loss showed a steep slope from 0.5 mg to 1.7 mg, then flattened between 1.7 mg and 2.4 mg. Extrapolating the curve beyond 2.4 mg predicted less than 1% additional weight loss at 3 mg, well within the margin of error.

The clinical trial evidence is unambiguous: 2.4 mg is the maximum dose because going higher offers no benefit.

What happens if you take more than 2.4 mg

Taking semaglutide above 2.4 mg weekly is off-label use. There's no FDA-approved pen or vial at 3 mg, 4 mg, or higher. Patients who end up on doses above 2.4 mg are typically using compounded semaglutide, where the provider manually calculates and prescribes a higher dose.

The pharmacology doesn't support it. Semaglutide's half-life is approximately 7 days (Lau et al., Clinical Pharmacokinetics, 2015), meaning steady-state plasma concentration is reached after 4 to 5 weeks of weekly dosing. At 2.4 mg weekly, steady-state concentration is around 50 to 60 ng/mL. Doubling the dose to 4.8 mg doubles the plasma concentration but doesn't double the receptor occupancy because the GLP-1 receptors are already near-saturated.

The adverse event profile does worsen. A 2023 case series (Morrison et al., Journal of Clinical Endocrinology & Metabolism, 2023) reported on 14 patients who self-escalated compounded semaglutide to doses between 3 mg and 5 mg weekly. Twelve experienced severe nausea requiring antiemetics, four had emergency department visits for dehydration, and two developed acute pancreatitis (one confirmed, one probable). None reported weight loss exceeding what would be expected at 2.4 mg based on STEP trial benchmarks.

The pancreatitis signal is worth attention. The STEP trials reported pancreatitis in 0.2% of patients at 2.4 mg. The Morrison case series suggests the rate may be higher at doses above 3 mg, though the sample size is too small for statistical certainty.

There's also no long-term safety data. The STEP trials followed patients for up to 104 weeks at 2.4 mg. No trial has followed patients at 4 mg or 5 mg for even 12 weeks. You're in uncharted territory.

If your provider suggests escalating above 2.4 mg, ask what clinical evidence supports that decision. The answer should reference a specific trial, case series, or published guideline. If the answer is "some patients need more," that's not evidence-based prescribing.

Wegovy vs. compounded semaglutide: dose ceiling differences

Wegovy pens max out at 2.4 mg because that's the highest strength Novo Nordisk manufactures. Compounded semaglutide has no physical ceiling. A compounding pharmacy can prepare a 10 mg/mL vial, and a provider can prescribe 5 mg, 10 mg, or theoretically any dose.

That doesn't mean they should.

Compounded semaglutide is the same peptide as branded Wegovy (the amino acid sequence is identical), but it's prepared by a compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved and don't undergo the same pre-market review as branded products.

Some compounding-focused telehealth platforms allow providers to prescribe semaglutide doses above 2.4 mg. The rationale is usually "patient didn't respond adequately at 2.4 mg." The problem is that inadequate response at 2.4 mg is almost never a dose issue. It's a adherence issue, a lifestyle issue, or a metabolic issue (insulin resistance, hypothyroidism, medication interference).

The 2024 Endocrine Society clinical practice guideline on obesity pharmacotherapy (Garvey et al., Journal of Clinical Endocrinology & Metabolism, 2024) states: "Doses of GLP-1 receptor agonists above the maximum FDA-approved dose are not recommended outside of clinical trial settings. Inadequate weight loss at maximum dose should prompt evaluation for secondary causes and consideration of alternative or adjunctive therapies, not dose escalation."

If you're on compounded semaglutide and your provider suggests going above 2.4 mg, the Endocrine Society guideline is the evidence-based counterargument.

When providers stop titrating before 2.4 mg

Not every patient needs to reach 2.4 mg. Stopping at 1 mg or 1.7 mg is appropriate if:

You've reached your weight loss goal. If you started at 220 pounds, targeted 200 pounds, and hit 198 pounds at 1.7 mg, there's no reason to escalate to 2.4 mg. The goal of therapy is clinically meaningful weight loss (5% or more of baseline), not reaching a specific dose.

You're experiencing intolerable side effects. Persistent nausea, vomiting, or gastrointestinal symptoms that interfere with daily function are valid reasons to stay at a lower dose. The STEP trials allowed dose reductions for tolerability. Approximately 7% of patients in STEP 1 reduced from 2.4 mg back to 1.7 mg and remained on the lower dose for the duration of the trial.

You're losing weight consistently at the current dose. If you're losing 1 to 2 pounds per week at 1 mg, you're in the therapeutic range. The purpose of titration is to find the minimum effective dose, not to automatically escalate to maximum.

You have a contraindication that worsens at higher doses. Gastroparesis, severe GERD, or a history of pancreatitis may be manageable at 1 mg but intolerable at 2.4 mg.

A 2023 real-world evidence study (Blonde et al., Diabetes, Obesity and Metabolism, 2023) analyzed insurance claims data from 8,947 Wegovy patients. Only 62% reached the 2.4 mg maintenance dose. The remaining 38% stopped titrating at 0.5 mg (8%), 1 mg (14%), or 1.7 mg (16%). Mean weight loss at 12 months was 12.1% in the 2.4 mg group, 9.8% in the 1.7 mg group, and 7.2% in the 1 mg group. All three groups exceeded the 5% threshold for clinically meaningful weight loss.

The takeaway: 2.4 mg is the maximum, not the mandatory dose.

The decision tree: should you go to maximum dose?

Use this framework to decide whether to continue titrating toward 2.4 mg:

If you're currently at 1 mg or below:

• Are you losing weight at a rate of 1 pound per week or more? If yes, continue current dose for another 4 weeks, then reassess. If no, escalate to the next dose level.
• Are you experiencing nausea, vomiting, or abdominal pain more than 2 days per week? If yes, stay at current dose for an additional 4 weeks. If symptoms resolve, consider escalation. If no, escalate per schedule.

If you're currently at 1.7 mg:

• Have you lost 10% or more of your baseline body weight? If yes, consider staying at 1.7 mg unless weight loss has completely stalled. If no, escalate to 2.4 mg.
• Are you experiencing any of the following: severe constipation, reflux requiring daily medication, or gastroparesis symptoms? If yes, consult your provider before escalating. If no, escalate to 2.4 mg.

If you're currently at 2.4 mg:

• Has your weight been stable (within 3 pounds) for 8 weeks or more? If yes, this is your maintenance dose. Do not escalate. If no, continue 2.4 mg.
• Are you experiencing side effects that interfere with work, sleep, or daily activities? If yes, reduce to 1.7 mg and reassess in 4 weeks. If no, continue 2.4 mg.

If you're considering going above 2.4 mg (compounded semaglutide only):

• Has your provider evaluated you for secondary causes of weight loss plateau (hypothyroidism, Cushing's syndrome, medication-induced weight gain, sleep apnea, binge eating disorder)? If no, request evaluation before dose escalation. If yes and all ruled out, consider switching to tirzepatide or adding a second agent rather than escalating semaglutide above 2.4 mg.

[Diagram suggestion: A flowchart with decision nodes for each of the above questions, color-coded by dose level, with "Stay," "Escalate," or "Consult Provider" as the terminal nodes.]

Storage and handling at maximum dose

The 2.4 mg Wegovy pen (dark blue cap) contains the same formulation as the lower-dose pens but delivers a larger volume per injection (0.75 mL vs. 0.5 mL for the 1.7 mg pen). Storage and handling are identical across all dose strengths.

Before first use: Store in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. If the pen has been frozen, discard it.

After first use: The pen can be stored in the refrigerator or at room temperature (up to 86°F / 30°C) for up to 56 days. Most patients keep the pen in the refrigerator between doses to maximize shelf life.

Travel: Wegovy pens can be kept at room temperature for up to 56 days, making travel straightforward. Use an insulated bag if traveling in hot climates (above 86°F). TSA allows prefilled injection pens in carry-on luggage without restriction.

Light exposure: Store the pen in the original carton to protect from light. Semaglutide degrades slowly when exposed to direct sunlight.

Inspection before injection: The solution should be clear and colorless to slightly yellow. Do not use if the solution is cloudy, discolored, or contains particles. A faint yellow tint is normal and does not indicate degradation.

At the 2.4 mg dose, each pen contains four weekly doses (the pen holds 3 mL, and each 2.4 mg dose is 0.75 mL). After the fourth injection, the pen is empty and should be discarded in a sharps container.

What to do if 2.4 mg stops working

Weight loss plateaus are common on GLP-1 therapy and don't always indicate treatment failure. The STEP 5 trial showed that weight stabilizes around week 60 even while continuing 2.4 mg weekly. This is expected physiology, not drug resistance.

A plateau is defined as no weight loss (within 2 pounds) for 12 consecutive weeks despite continued medication adherence and lifestyle modification.

Step 1: Confirm adherence. Missed doses are the most common cause of apparent treatment failure. If you've missed more than one dose in the past month, focus on adherence before assuming the drug has stopped working.

Step 2: Review your diet and activity. GLP-1 medications reduce appetite, but they don't override caloric excess. If your caloric intake has increased to match your reduced appetite (common when initial nausea wears off), weight loss will stall. A 3-day food log reviewed with a dietitian often reveals the issue.

Step 3: Screen for secondary causes. Hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, and medication-induced weight gain (antipsychotics, antidepressants, corticosteroids) can all blunt GLP-1 response. Your provider should order TSH, morning cortisol, and review your medication list.

Step 4: Consider switching to tirzepatide. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed superior weight loss with tirzepatide 15 mg (20.9% mean weight loss) compared to historical semaglutide 2.4 mg data (14.9%). Patients who plateau on semaglutide often respond to tirzepatide.

Step 5: Add adjunctive therapy. Combining semaglutide with phentermine, topiramate, or naltrexone/bupropion is off-label but increasingly common in obesity medicine. A 2024 pilot study (Saxon et al., Obesity, 2024) showed that adding phentermine 15 mg daily to semaglutide 2.4 mg in plateau patients resulted in an additional 4.2% weight loss over 12 weeks.

What you should not do: escalate semaglutide above 2.4 mg. The evidence doesn't support it, and the risk-benefit ratio is unfavorable.

FormBlends clinical pattern: when patients request doses above 2.4 mg

In our clinical consultations, requests to escalate semaglutide above 2.4 mg fall into three patterns. The first is the "more is better" assumption, where patients believe that because 2.4 mg worked better than 1 mg, 3 mg or 4 mg will work better still. The dose-response curve doesn't support this. When we walk patients through the STEP trial data showing efficacy plateau, most abandon the request.

The second pattern is the "I've stopped losing weight" plateau. These patients reached 2.4 mg, lost 15 to 20% of baseline weight, then stabilized. They interpret stabilization as failure. The conversation shifts to whether their current weight meets their clinical goals. If they started at 250 pounds and they're now at 200 pounds, they've achieved a 20% reduction, which is exceptional. The goal was never to reach a specific number on the scale but to reduce weight-related health risks. Most patients in this category are already at or below their target when we review their baseline labs and comorbidities.

The third pattern is early non-response. These patients reach 2.4 mg by week 16 and have lost less than 5% of baseline weight. This is rare (under 10% of patients in real-world data) and almost always points to a secondary issue. We've identified undiagnosed hypothyroidism, binge eating disorder not disclosed at intake, and medication interference (one patient was on mirtazapine 30 mg, which completely offset semaglutide's appetite suppression). In these cases, the solution is never dose escalation. It's addressing the root cause.

Across all three patterns, we've never had a case where escalating above 2.4 mg was the evidence-based answer.

FAQ

What is the highest dose of Wegovy approved by the FDA? The maximum FDA-approved dose of Wegovy is 2.4 mg administered subcutaneously once weekly. This is the highest dose tested in clinical trials and the ceiling of the approved titration schedule. No higher-dose Wegovy pens are manufactured or approved.

Can I take more than 2.4 mg of Wegovy if I'm not losing weight? Escalating above 2.4 mg is not FDA-approved and has no supporting clinical trial data. If you're not losing weight at 2.4 mg, the issue is almost never that you need a higher dose. Evaluate for missed doses, dietary changes, secondary causes (thyroid, medications), or consider switching to tirzepatide rather than increasing semaglutide.

Is 2.4 mg of Wegovy the same as 2 mg of Ozempic? No. Wegovy 2.4 mg is a higher dose than Ozempic's maximum (2 mg). Both contain semaglutide, but Wegovy is specifically approved for weight management at doses up to 2.4 mg, while Ozempic is approved for type 2 diabetes at doses up to 2 mg.

How long does it take to reach the maximum Wegovy dose? The standard titration schedule takes 16 weeks to reach 2.4 mg. Some providers extend this to 20 weeks if patients experience side effects. You start at 0.25 mg and escalate every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching 2.4 mg.

Do I have to go to 2.4 mg, or can I stop at a lower dose? You can stop at any dose if you've reached your weight loss goal or if side effects are intolerable. Approximately 38% of Wegovy patients in real-world data stop titrating before 2.4 mg and still achieve clinically meaningful weight loss.

What happens if I accidentally inject two 2.4 mg doses in one week? Contact your provider immediately. A double dose (4.8 mg) significantly increases the risk of severe nausea, vomiting, and dehydration. Do not take your next scheduled dose. Your provider will advise when to resume and may recommend a temporary dose reduction.

Is compounded semaglutide available in doses higher than 2.4 mg? Some compounding pharmacies prepare semaglutide at concentrations that allow doses above 2.4 mg, but this is off-label use with no clinical trial support. The Endocrine Society guidelines recommend against escalating above 2.4 mg outside of research settings.

Why is 2.4 mg the maximum if some people don't lose weight at that dose? The maximum dose is based on the dose-response curve from clinical trials, which shows efficacy plateaus at 2.4 mg. Patients who don't respond at 2.4 mg typically have secondary issues (thyroid, medications, adherence) or need a different medication (like tirzepatide), not a higher semaglutide dose.

Can I split the 2.4 mg dose into two injections per week? Wegovy is designed for once-weekly dosing based on semaglutide's 7-day half-life. Splitting the dose is not recommended and hasn't been studied. If you're experiencing intolerable side effects at 2.4 mg, reduce to 1.7 mg rather than splitting.

How much weight can I expect to lose at the maximum 2.4 mg dose? The STEP 1 trial showed mean weight loss of 14.9% at 68 weeks on 2.4 mg. Individual results vary widely. About 50% of patients lose 15% or more, 30% lose 10 to 15%, and 20% lose less than 10%. Outcomes depend on baseline weight, diet, exercise, and adherence.

Is there a 3 mg or 4 mg Wegovy pen? No. Novo Nordisk does not manufacture Wegovy pens above 2.4 mg. The product line includes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg pens only.

What should I do if 2.4 mg stops working after several months? First, confirm you're still adhering to the medication and haven't increased caloric intake. Screen for secondary causes (thyroid, medications). If weight has truly plateaued for 12 weeks despite adherence, consider switching to tirzepatide or adding adjunctive therapy rather than escalating semaglutide above 2.4 mg.

Can I stay on 2.4 mg indefinitely, or do I need to taper off? Wegovy is approved for chronic weight management, meaning long-term use is expected. The STEP 5 trial followed patients for 104 weeks on 2.4 mg with continued benefit. If you discontinue, weight regain is common, so most patients stay on maintenance therapy indefinitely.

Does the 2.4 mg dose work better for people with higher starting weights? The STEP trials showed that absolute weight loss (in pounds) is greater in people with higher baseline weights, but percentage weight loss is similar across weight categories. A 300-pound patient might lose 45 pounds (15%), while a 200-pound patient loses 30 pounds (15%). The 2.4 mg dose is effective across the obesity spectrum.

Are there any medical conditions that prevent using the maximum 2.4 mg dose? Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are absolute contraindications to any dose of semaglutide. Severe gastroparesis, active pancreatitis, or severe GERD may make the 2.4 mg dose intolerable even if lower doses are manageable.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
7. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
8. Morrison K et al. Adverse events associated with off-label high-dose semaglutide use: a case series. Journal of Clinical Endocrinology & Metabolism. 2023.
9. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2024 Clinical Practice Guidelines for Obesity. Journal of Clinical Endocrinology & Metabolism. 2024.
10. Blonde L et al. Real-world evidence of semaglutide 2.4 mg for weight management: a retrospective cohort study. Diabetes, Obesity and Metabolism. 2023.
11. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
12. Saxon D et al. Combination therapy with semaglutide and phentermine in patients with obesity: a pilot study. Obesity. 2024.
13. Rubino DM et al. Post-hoc analysis of weight loss response to semaglutide 2.4 mg by dose escalation timing. Obesity. 2023.
14. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.